Signaling through the insulin-like growth factor 1 receptor (IGF-1R) is increasingly recognized as a precursor to and a potentiator of the malignant phenotype in preclincal models. The axis of proteins involved is complex, including two ligands, six binding proteins, IGF-1R, and IGF-2R, a non-signaling receptor, and two adaptor proteins. Circulating levels or tumor expression of IGF axis proteins has been correlated with risk of malignancy or poor prognosis of established cancer. IGF-1R interacts with other cellular receptors including epidermal growth factor receptor (EGFR), a validated drug target in HNSCC. We have observed that activation of IGF-1R signaling in cell lines promotes proliferation, survival, angiogenesis and invasion. Further, our data indicate that activation of IGF-1R can mediate resistance to EGF-R-targeted therapy and vice versa, suggesting an advantage to co-targeting EGFR and IGF-1 R. Thus, we hypothesize that cotargeting IGF-1 R and EGFR will be more successful than inhibition of either pathway alone in therapy of HNSCC. In this project, we will assess IGF axis protein expression and downstream proteins in tumor microarrays from patients resected for SCC of the oral tongue (Aim 1). Correlation of biomarkers with disease-specific survival will be explored, especially as regards the negative impact of nodal spread and extracapsular invasion, an invasive phenotype. We will study cooperation of IGF-1 R and EGFR in mediating proliferative, angiogenic, and invasive activities of HNSCC lines in vitro (Aim 2). Antitumor effects of the anti- IGF-1R humanized monoclonal antibody (IMC-A12) will be studied alone or with anti-EGFR antibody cetuximab, using multiple complementary models, including a highly metastatic cell line, in orthotopic tongue xenograft models (Aim 3). The activity of IMC-A12 as monotherapy or combined with cetuximab will be defined in a randomized trial for patients with recurrent HNSCC (Aim 4), targeting a 50% improvement in progression-free survival compared to cetuximab alone. Tissue and blood-based biomarkers will be assessed and correlations with clinical outcomes explored. This proposal builds on our results implicating IGF axis signaling in potentiating the malignant phenotype of HNSCC and promising data co-targeting EGFR and IGF-1 R in therapy of HNSCC. Insights to be gained from this work, both preclincal and clinical aims, have the potential to facilitate targeting therapy to those patients most likely to benefit.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA097007-10
Application #
8380167
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
2014-07-31
Budget Start
2012-08-01
Budget End
2013-07-31
Support Year
10
Fiscal Year
2012
Total Cost
$343,462
Indirect Cost
$108,627
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Zhang, Hua; Sturgis, Erich; Zhu, Lijun et al. (2018) The Modifying Effect of a Functional Variant at the miRNA Binding Site in E2F1 Gene on Recurrence of Oropharyngeal Cancer Patients with Definitive Radiotherapy. Transl Oncol 11:633-638
Gleber-Netto, Frederico O; Zhao, Mei; Trivedi, Sanchit et al. (2018) Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma. Cancer 124:84-94
(2018) Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. Nat Genet 50:668-681
Jurkovic, Ines-Ana; Kocak-Uzel, Esengul; Mohamed, Abdallah Sherif Radwan et al. (2018) Dosimetric and Radiobiological Evaluation of Patient Setup Accuracy in Head-and-neck Radiotherapy Using Daily Computed Tomography-on-rails-based Corrections. J Med Phys 43:28-40
Huckins, L M; Hatzikotoulas, K; Southam, L et al. (2018) Investigation of common, low-frequency and rare genome-wide variation in anorexia nervosa. Mol Psychiatry 23:1169-1180
M. D. Anderson Cancer Center Head and Neck Quantitative Imaging Working Group (2018) Investigation of radiomic signatures for local recurrence using primary tumor texture analysis in oropharyngeal head and neck cancer patients. Sci Rep 8:1524
Gadhikar, Mayur A; Zhang, Jiexin; Shen, Li et al. (2018) CDKN2A/p16 Deletion in Head and Neck Cancer Cells Is Associated with CDK2 Activation, Replication Stress, and Vulnerability to CHK1 Inhibition. Cancer Res 78:781-797
Zhang, Tongwu; Choi, Jiyeon; Kovacs, Michael A et al. (2018) Cell-type-specific eQTL of primary melanocytes facilitates identification of melanoma susceptibility genes. Genome Res 28:1621-1635
Saintigny, Pierre; Mitani, Yoshitsugu; Pytynia, Kristen B et al. (2018) Frequent PTEN loss and differential HER2/PI3K signaling pathway alterations in salivary duct carcinoma: Implications for targeted therapy. Cancer 124:3693-3705
Pinnix, Chelsea C; Ng, Andrea K; Dabaja, Bouthaina S et al. (2018) Positron emission tomography-computed tomography predictors of progression after DA-R-EPOCH for PMBCL. Blood Adv 2:1334-1343

Showing the most recent 10 out of 370 publications